---
title: "ANKE BIO: The invested company PA3-17 injection has been approved to enter the critical Phase II clinical trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257708376.md"
description: "ANKE BIO announced that its affiliated companies, Boshengji Pharmaceutical Technology Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., have been approved by the National Medical Products Administration to conduct the key Phase II clinical trial of PA3-17 injection. This injection is the world's first autologous CAR-T cell therapy product targeting CD7, aimed at treating adult relapsed and refractory CD7-positive hematologic malignancies"
datetime: "2025-09-17T10:48:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257708376.md)
  - [en](https://longbridge.com/en/news/257708376.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257708376.md)
generator: "portal-rs"
---

# ANKE BIO: The invested company PA3-17 injection has been approved to enter the critical Phase II clinical trial

ANKE BIO announced that recently, its affiliated companies, Boshengji Pharmaceutical Technology Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., received the Minutes of the communication meeting for Phase II of PA3-17 injection issued by the Drug Evaluation Center of the National Medical Products Administration, agreeing to the applicant's request to conduct a pivotal Phase II clinical trial for PA3-17 injection. PA3-17 injection is the world's first autologous CAR-T cell therapy product targeting CD7, independently developed by Boshengji Anke, which has received approval for new drug clinical trials for the treatment of adult relapsed and refractory CD7-positive hematologic and lymphatic malignancies

### Related Stocks

- [300009.CN](https://longbridge.com/en/quote/300009.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [Frozen blueberries recall categorized under FDA's highest Class I risk level](https://longbridge.com/en/news/296506599.md)
- [Rapala VMC: Strong H1 sales and profit growth led to upgraded full-year outlook amid ongoing trade risks](https://longbridge.com/en/news/296480810.md)
- [DIMRI: H1 2026 net profit rose to ₪495.6M on revenue of ₪780.5M, with robust liquidity and equity](https://longbridge.com/en/news/296448412.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**